dc.creatorVase, MajaØlholm
dc.creatorLudvigsen, Maja
dc.creatorBendix, Knud
dc.creatorDutoit, Stephen H.
dc.creatorHjortebjerg, Rikke
dc.creatorPetruskevicius, Irma
dc.creatorMøller, Michael B.
dc.creatorPedersen, Gitte
dc.creatorDenton, Paul W.
dc.creatorHonoré, Bent
dc.creatorRabinovich, Gabriel Adrián
dc.creatorLarsen, Carsten S.
dc.creatorD'Amore, Francesco
dc.date.accessioned2018-11-05T23:40:22Z
dc.date.accessioned2018-11-06T14:02:43Z
dc.date.available2018-11-05T23:40:22Z
dc.date.available2018-11-06T14:02:43Z
dc.date.created2018-11-05T23:40:22Z
dc.date.issued2017-10-23
dc.identifierVase, MajaØlholm; Ludvigsen, Maja; Bendix, Knud; Dutoit, Stephen H.; Hjortebjerg, Rikke; et al.; Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma; Lippincott Williams; Aids; 31; 16; 23-10-2017; 2311-2313
dc.identifier0269-9370
dc.identifierhttp://hdl.handle.net/11336/63728
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1882180
dc.description.abstractAt AHIV-1 infection, the binding of the viral envelopeproteins to CD4þ is essential for viral transmission, andthis process is facilitated by interaction with the highlyconserved host lectin, galectin-1 (Gal-1) [1?3]. Withinthe tumor microenvironment, Gal-1 is expressed by bothtumor and stromal cells where it promotes tumorimmune escape and favors hypoxia-driven angiogenesis[4?6]. In sporadically occurring Hodgkin lymphoma,high Gal-1 expression at diagnosis is associated withpoorer treatment response [7], and high soluble Gal-1(sGal-1) correlates with adverse disease characteristics [8].Previous studies have shown that targeted inhibition ofGal-1 prevents tumor-induced immunosuppression[9,10] as well as inhibits tumor growth and metastasisin various tumor models [6,11?13].In conclusion, the results of our study indicate that Gal-1 is significantly associated with risk of lymphoma in HIV-infected individuals and may represent an attractive futuretarget for the management of HIV-associated lymphoma.
dc.languageeng
dc.publisherLippincott Williams
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/pubmed?pmid=28991028
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/QAD.0000000000001622
dc.relationinfo:eu-repo/semantics/altIdentifier/pmid/28991028
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectGALECTIN-1
dc.subjectHIV
dc.subjectLYMPHOMA
dc.subjectPROGNOSIS
dc.titlePredictive value of galectin-1 in the development and progression of HIV-associated lymphoma
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución